Evidence map›Paper›PMID 30781383›Full record

ArticlePharmaceutics2019

Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites.

Makoto Anraku, Ryo Tabuchi, Miwa Goto, Daisuke Iohara, Yasuyuki Mizukai, Yuji Maezaki, Akihiro Michihara, Daisuke Kadowaki, Masaki Otagiri, Fumitoshi Hirayama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Makoto AnrakuFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. anraku@ph.sojo-u.ac.jp.ORCID 0000-0001-8249-6983
Ryo TabuchiFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. sojo_tabuchi@yahoo.co.jp.
Miwa GotoFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. chaiahchai@gmail.com.
Daisuke IoharaFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. dio@ph.sojo-u.ac.jp.
Yasuyuki MizukaiNippon Kayaku Food Techno Co., Ltd., 219, Iwahanamachi, Takasaki, Gunma 370-1208, Japan. yasuyuki.mizukai@nipponkayaku.co.jp.
Yuji MaezakiNippon Kayaku Food Techno Co., Ltd., 219, Iwahanamachi, Takasaki, Gunma 370-1208, Japan. yuji.maezaki@nipponkayaku.co.jp.
Akihiro MichiharaFaculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 1 Sanzo, Gakuen-cho, Fukuyama 729-0292, Japan. mitihara@fupharm.fukuyama-u.ac.jp.
Daisuke KadowakiFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. d-kado@ph.sojo-u.ac.jp.
Masaki OtagiriFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. otagirim@ph.sojo-u.ac.jp.
Fumitoshi HirayamaFaculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan. fhira@ph.sojo-u.ac.jp.
Sojo University · JPNippon Kayaku (Japan) · JPFukuyama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the A

Indexed as

antihypertensive effectschitosanextend-releasematrix tabletsulfobutyl ether β-cyclodextrin

Identifiers

PMID30781383
PMCPMC6409563
OpenAlexW2914250225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.